Supplements useless in cancer prevention, despite marketing claims

It is a multi-billion dollar industry thanks to as many as half of all US adults buying into their marketing campaigns, but the supplement industry lacks any evidence that comes even remotely close to supporting such a massive and influential business. The fact that some of them are marketed as anti-cancer, or as cancer preventives, is potentially dangerous and demands government regulation, according to researchers from the University of California. Their work has been published in the Journal of the National Cancer Institute.

What they found was the only evidence that dietary antioxidants -- including beta-carotene, alpha-tocopherol, and vitamin C -- did in fact encourage growth of normal cells and tissue and inhibit growth of abnormal tissue was in pre-clinical trials--in the lab, in other words. Trials featuring actual humans never supported the pre-clinical evidence.

Furthermore, their review determined that:

  • Beta-carotene did not prevent recurrence of (non-melanoma) skin cancer
  • Beta-carotene, alpha-tocopherol, and vitamin C failed to prevent recurrence of colonic adenomas
  • Beta-carotene, vitamin A, and alpha-tocopherol did not prevent lung cancer
  • Vitamins C and E did not protect against cancer
  • Alpha-tocopherol, vitamin C, and beta-carotene had no effect on cancer incidence or mortality
  • Beta-carotene and vitamins A, C, and E -- alone or in combination -- did not prevent gastrointestinal cancers
  • Alpha-tocopherol and selenium failed to prevent prostate cancer in average-risk men

Source: Medpage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap